Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2000-07-20
2002-12-17
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S430000, C424S422000, C424S489000, C424S502000
Reexamination Certificate
active
06495157
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention is directed to a treatment for bacterial vaginosis (BV). The exact etiology of BV is unclear although it appears to result from an overgrowth of organisms in the vaginal flora. Although generally a mild condition, BV is distressing to the patient because of the unpleasant vaginal odor and discharge. In addition, it is epidemiologically linked to several urogenital diseases. Clindamycin vaginal cream (CVC) 100 mg per day for 7 days is a standard treatment for BV. It has recently been demonstrated that a 3-day treatment course of CVC is as effective as a 7-day course. However, even with a 3-day treatment, the use of creams is considered to be inconvenient. A vaginal ovule (suppository) formulation containing clindamycin would offer patients an alternative, more convenient dosage form. Therefore, the development of a vaginal suppository having at least the same efficacy as CVC was undertaken. As a result of this development effort, it was discovered that Hard Fat NF suppository bases significantly increased the storage stability of clindamycin.
SUMMARY OF THE INVENTION
We have developed a highly storage-stable composition for vaginal administration of clindamycin which comprises a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat suppository base, preferably Hard Hat NF grade. Hard Fat bases are a mixture of glyceride esters of higher saturated fatty acids. The Hard Fat NF suppository bases provide a clindamycin product having increased stability over the CVC formulation while providing equivalent efficacy against BV.
REFERENCES:
patent: WO-97/44032 (1997-11-01), None
Bowman Phil Bryan
Chao Robert Shih-Liang
Pena Lorraine Elisabeth
Pesheck Carolyn V.
Bennett Rachel M.
King Karen B.
Page Thurman K.
Pharmacia & Upjohn Company
Pokras Bruce A.
LandOfFree
Intravaginal clindamycin ovule composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intravaginal clindamycin ovule composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravaginal clindamycin ovule composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2961531